Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or standard-of-care cetuximab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 2 visits at the study clinic for each cycle (duration of cycle is 4 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona histologicznie lub cytologicznie choroba nowotworowa - rak gruczołowy jelita grubego po lewej stronie, który nie da się usunąć chirurgicznie lub rozprzestrzenił się na inne części ciała
- •Wynik testu genetycznego (NGS) potwierdzający brak mutacji w genach KRAS i NRAS
- •Pacjent nie otrzymywał dotychczas żadnego leczenia systemowego (całego organizmu) z powodu zaawansowanego raka jelita grubego
- •Pacjent kwalifikuje się do leczenia chemioterapią (mFOLFOX6 lub FOLFIRI) zgodnie z lokalnymi wytycznymi
✗ Disqualifies
- •Obecność mutacji w genie BRAF lub innych określonych zmian genetycznych (MSI-H, dMMR, mutacja HRAS)
- •Wcześniejsze leczenie lekami celowanymi w receptor EGF (cetuximab, panitumumab lub inne)
- •Znany deficyt enzymu DPD lub mutacje genetyczne DPYD uniemożliwiające metabolizm chemioterapii
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
PanOncology
Manati, Puerto Rico
Trial contact
Genmab Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.